EA200401043A1 - Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm ) - Google Patents

Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm )

Info

Publication number
EA200401043A1
EA200401043A1 EA200401043A EA200401043A EA200401043A1 EA 200401043 A1 EA200401043 A1 EA 200401043A1 EA 200401043 A EA200401043 A EA 200401043A EA 200401043 A EA200401043 A EA 200401043A EA 200401043 A1 EA200401043 A1 EA 200401043A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sarm
androgen receptor
enzyme
type
metabolite
Prior art date
Application number
EA200401043A
Other languages
English (en)
Other versions
EA013399B1 (ru
Inventor
Митчелл С. Стейнер
Карен А. Веверка
Дуэйн Д. Миллер
Джеймс Т. Долтон
Венквинг Джао
Original Assignee
Джи Ти Икс, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джи Ти Икс, ИНК. filed Critical Джи Ти Икс, ИНК.
Publication of EA200401043A1 publication Critical patent/EA200401043A1/ru
Publication of EA013399B1 publication Critical patent/EA013399B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47042-Quinolinones, e.g. carbostyril
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28Antiandrogens

Abstract

Это изобретение обеспечивает способ лечения, предупреждения, подавления, ингибирования или снижение заболеваемости доброкачественной гиперплазией простаты у пациентов-мужчин путем введения этому пациенту селективного модулятора рецептора андрогенов (SARM) и/или его аналога, производного, изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксида или любого их сочетания, описанного в изобретении. Кроме того, это изобретение обеспечивает способ лечения пациентов, страдающих от выпадения волос, который включает стадию введения пациенту терапевтически эффективного количества ингибитора фермента 5α-редуктазы типа 1 и/или типа 2, где указанный ингибитор представляет собой селективный модулятор рецептора андрогенов (SARM) и/или его аналог, производное, изомер, метаболит, фармацевтически приемлемую соль, фармацевтический продукт, гидрат, N-оксид или любое их сочетание, описанное в изобретении. Это изобретение также обеспечивает способ ингибирования фермента 5α-редуктазы типа 1 и/или типа 2, который включает контактирование фермента с эффективным ингибирующим 5α-редуктазу количеством селективного модулятора рецептора андрогенов (SARM) и/или его аналога, производного, изомера, метаболита, фармацевтически приемлемой соли, фармацевтического продукта, гидрата, N-оксида или их любого сочетания, описанного в изобретении.Отчет о международном поиске был опубликован 2004.02.26.
EA200401043A 2002-02-07 2003-02-06 Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm) EA013399B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35430002P 2002-02-07 2002-02-07
US36299702P 2002-03-11 2002-03-11
PCT/US2003/003447 WO2003065992A2 (en) 2002-02-07 2003-02-06 Treating benign prostate hyperplasia with sarms

Publications (2)

Publication Number Publication Date
EA200401043A1 true EA200401043A1 (ru) 2005-06-30
EA013399B1 EA013399B1 (ru) 2010-04-30

Family

ID=27737453

Family Applications (2)

Application Number Title Priority Date Filing Date
EA200901492A EA200901492A1 (ru) 2002-02-07 2003-02-06 Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm)
EA200401043A EA013399B1 (ru) 2002-02-07 2003-02-06 Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200901492A EA200901492A1 (ru) 2002-02-07 2003-02-06 Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm)

Country Status (21)

Country Link
US (2) US7776921B2 (ru)
EP (1) EP1480634B1 (ru)
JP (3) JP4677516B2 (ru)
KR (2) KR101032661B1 (ru)
CN (2) CN1646115B (ru)
AT (1) ATE518537T1 (ru)
AU (2) AU2003216174C1 (ru)
BR (1) BRPI0307699A2 (ru)
CA (2) CA2475108A1 (ru)
CY (1) CY1111917T1 (ru)
DK (1) DK1480634T3 (ru)
EA (2) EA200901492A1 (ru)
GE (1) GEP20074122B (ru)
HK (1) HK1068103A1 (ru)
HR (2) HRP20040793A2 (ru)
IL (2) IL163380A (ru)
MX (1) MXPA04007639A (ru)
PT (1) PT1480634E (ru)
RS (1) RS69704A (ru)
TW (2) TWI374737B (ru)
WO (1) WO2003065992A2 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493403B2 (en) 2000-08-24 2016-11-15 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759520B2 (en) 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7919647B2 (en) 2000-08-24 2011-04-05 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7645898B2 (en) * 2000-08-24 2010-01-12 University Of Tennessee Research Foundation Selective androgen receptor modulators and method of use thereof
US7855229B2 (en) 2000-08-24 2010-12-21 University Of Tennessee Research Foundation Treating wasting disorders with selective androgen receptor modulators
US20040260108A1 (en) * 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7622503B2 (en) 2000-08-24 2009-11-24 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
CN1726020A (zh) * 2002-10-16 2006-01-25 Gtx公司 用sarm治疗老年男性雄激素缺乏(adam)相关的疾病
US20060276539A1 (en) * 2002-10-16 2006-12-07 Dalton James T Treating Androgen Decline in Aging Male (ADAM)- associated conditions with SARMS
US8309603B2 (en) 2004-06-07 2012-11-13 University Of Tennessee Research Foundation SARMs and method of use thereof
FI20030958A0 (fi) * 2003-06-27 2003-06-27 Orion Corp Uusia yhdisteitä
DE602004026583D1 (de) * 2003-06-27 2010-05-27 Orion Corp Als androgenrezeptormodulatoren geeignete propionamidderivate
EA013738B1 (ru) * 2003-10-14 2010-06-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Лечение нарушений костной ткани с использованием селективных модуляторов адрогенных рецепторов
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
UA87854C2 (en) * 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
US9889110B2 (en) 2004-06-07 2018-02-13 University Of Tennessee Research Foundation Selective androgen receptor modulator for treating hormone-related conditions
US20110237664A1 (en) * 2004-06-07 2011-09-29 Dalton James T Selective androgen receptor modulators for treating diabetes
GEP20094851B (en) * 2004-06-07 2009-12-10 The Univ Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
PT1753417E (pt) * 2004-06-07 2012-07-05 Univ Tennessee Res Foundation Um modulador selectivo de receptor de androgénio e as suas utilizações medicinais
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
US7601725B2 (en) 2004-07-16 2009-10-13 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as Aurora kinase inhibitors
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
WO2007123682A2 (en) * 2006-04-03 2007-11-01 Medexis S.A. Detection of membrane androgen receptor (mar) agents
US9844528B2 (en) 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
US10010521B2 (en) 2006-08-24 2018-07-03 University Of Tennessee Research Foundation SARMs and method of use thereof
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
US9730908B2 (en) 2006-08-24 2017-08-15 University Of Tennessee Research Foundation SARMs and method of use thereof
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
EP2822556A1 (en) * 2012-03-07 2015-01-14 Ligand Pharmaceuticals Inc. Steroid hormone and cholesterol pathways as one unified homestatic system
CN104487114A (zh) 2012-04-06 2015-04-01 安塔雷斯药品公司 针头辅助喷射注射给予睾酮组合物
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
DK2872482T3 (da) 2012-07-13 2020-09-21 Oncternal Therapeutics Inc En fremgangsmåde til behandling af brystkræft med selektiv androgenreceptormodulator (sarm)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
WO2015122858A1 (en) 2014-02-15 2015-08-20 Erdal Can Alkoçlar A composition containing synthetic components formed for suppressing ribonucleotide reductase
HUP1400294A2 (hu) 2014-06-13 2015-12-28 Skillpharm Kft Clopidogrel új alkalmazása
CA2964371A1 (en) * 2014-10-16 2016-04-21 Gtx, Inc. Methods of treating urological disorders using sarms

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644970A (en) * 1899-02-06 1900-03-06 Thomas Graham Donaldson Dental flask.
US935044A (en) * 1909-01-12 1909-09-28 Lenn G Mccorry Valve.
US935045A (en) * 1909-06-19 1909-09-28 Robert J Mckelvey Turn-table.
GB1360001A (en) 1971-06-16 1974-07-17 Scherico Ltd Pharmaceutical compositions comprising substituted anilides
US3875229A (en) * 1972-11-24 1975-04-01 Schering Corp Substituted carboxanilides
JPS6044294B2 (ja) 1976-04-15 1985-10-02 帝国臓器製薬株式会社 アニリド誘導体
US4139638A (en) * 1976-09-23 1979-02-13 Schering Corporation Methods for the treatment of hirsutism
EP0002309B1 (en) * 1977-10-12 1982-12-01 Imperial Chemical Industries Plc Acylanilides, process for their manufacture and pharmaceutical and veterinary compositions containing them
US4191775A (en) * 1977-12-15 1980-03-04 Imperial Chemical Industries Limited Amide derivatives
NZ197008A (en) 1980-05-22 1984-10-19 Ici Ltd Acylanilide derivatives and pharmaceutical compositions
JPS57171904A (en) * 1981-04-15 1982-10-22 Mitsubishi Petrochem Co Ltd Tri- or tetra-substituted phenoxycarboxylic acid anilide type herbicide
ATE28864T1 (de) * 1982-07-23 1987-08-15 Ici Plc Amide-derivate.
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
GB8617652D0 (en) * 1986-07-18 1986-08-28 Ici Plc Acylanilide derivatives
US5162504A (en) * 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
CA2181358A1 (en) 1994-01-21 1995-07-27 Nancy M. Gray Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
US5609849A (en) * 1994-03-11 1997-03-11 The Trustees Of The University Of Pennsylvania Serotonin (5-HT1A) receptor ligands and imaging agents
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
WO1998005962A1 (en) 1996-08-02 1998-02-12 Panvera Corporation A method for quantitating competitive binding of molecules to proteins utilizing fluorescence polarization
US6995284B2 (en) 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6492554B2 (en) * 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7205437B2 (en) * 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US20090264534A1 (en) * 1996-11-27 2009-10-22 Dalton James T Selective androgen receptor modulators
US6071957A (en) * 1996-11-27 2000-06-06 The University Of Tennessee Research Corporation Irreversible non-steroidal antagonist compound and its use in the treatment of prostate cancer
JPH10182457A (ja) * 1996-12-25 1998-07-07 Yuichi Hashimoto 抗アンドロゲン剤
WO1998053826A1 (en) * 1997-05-30 1998-12-03 The University Of Tennessee Research Corporation Non-steroidal agonist compounds and their use in male hormone therapy
WO1998055153A1 (en) 1997-06-04 1998-12-10 The University Of Tennessee Research Corporation Non-steroidal radiolabeled agonist/antagonist compounds and their use in prostate cancer imaging
JPH1135558A (ja) * 1997-07-18 1999-02-09 Zeria Pharmaceut Co Ltd 3−ベンゾイルインドール誘導体及びそれらを含有する医薬
GB9919778D0 (en) * 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
JP2003511467A (ja) 1999-10-14 2003-03-25 ブリストル−マイヤーズ スクイブ カンパニー アンドロゲンレセプターリガンド結合ドメインの結晶構造
HUP0203785A2 (hu) 1999-10-19 2003-04-28 Nobex Corporation Eljárás Casodex enantiomereinek, származékainak és intermediereinek előállítására
BR0015124A (pt) 1999-10-27 2002-07-02 Nobex Corp Método de preparação de um enanciÈmero substancialmente puro
UA74826C2 (en) * 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
EP1299094A2 (en) 2000-06-28 2003-04-09 Bristol-Myers Squibb Company Selective androgen receptor modulators and methods for their identification, design and use
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
US6998500B2 (en) 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6838484B2 (en) 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
EP1401801B1 (en) * 2000-08-24 2006-11-02 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20070161608A1 (en) * 2001-12-06 2007-07-12 Dalton James T Selective androgen receptor modulators for treating muscle wasting
EP2289503B1 (en) 2001-12-06 2016-06-29 University of Tennessee Research Foundation Treating muscle wasting with selective androgen receptor modulators

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493403B2 (en) 2000-08-24 2016-11-15 University Of Tennessee Research Foundation Treating androgen decline in aging male (ADAM)-associated conditions with SARMs

Also Published As

Publication number Publication date
PT1480634E (pt) 2011-10-12
AU2003216174A1 (en) 2003-09-02
EP1480634A2 (en) 2004-12-01
KR20040089606A (ko) 2004-10-21
DK1480634T3 (da) 2011-11-14
CY1111917T1 (el) 2015-11-04
EA200901492A1 (ru) 2010-08-30
JP2010209102A (ja) 2010-09-24
EA013399B1 (ru) 2010-04-30
IL163380A (en) 2010-06-30
IL202675A (en) 2011-06-30
HRP20040793A2 (en) 2006-10-31
KR20100112659A (ko) 2010-10-19
EP1480634A4 (en) 2008-01-16
JP4677516B2 (ja) 2011-04-27
EP1480634B1 (en) 2011-08-03
CN101732298B (zh) 2012-09-19
TW200307537A (en) 2003-12-16
AU2003216174C1 (en) 2010-01-28
AU2003216174B8 (en) 2009-01-15
AU2003216174B2 (en) 2008-12-18
JP2013144713A (ja) 2013-07-25
JP2005522431A (ja) 2005-07-28
US7776921B2 (en) 2010-08-17
CN1646115B (zh) 2010-06-09
HK1068103A1 (en) 2005-04-22
TW200918043A (en) 2009-05-01
US20040053897A1 (en) 2004-03-18
RS69704A (en) 2006-12-15
CN101732298A (zh) 2010-06-16
KR101032661B1 (ko) 2011-05-06
MXPA04007639A (es) 2005-07-13
TWI374737B (en) 2012-10-21
HRP20100067A2 (hr) 2010-04-30
CA2689080C (en) 2011-07-05
WO2003065992A3 (en) 2004-02-26
BRPI0307699A2 (pt) 2015-06-16
WO2003065992A2 (en) 2003-08-14
GEP20074122B (en) 2007-06-11
AU2009201084A1 (en) 2009-04-09
US20100280107A1 (en) 2010-11-04
CA2475108A1 (en) 2003-08-14
US8088828B2 (en) 2012-01-03
CN1646115A (zh) 2005-07-27
ATE518537T1 (de) 2011-08-15
CA2689080A1 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
EA200401043A1 (ru) Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm )
IN2005KO00312A (ru)
WO2004092115A3 (en) Hydroxamates as therapeutic agents
NO20100093L (no) Peptidomimetiske protease-inhibitorer
DE60114994D1 (de) Blutplättchen-adp-rezeptor-inhibitoren
NO20014046L (no) Gabapentinderivater for forhindring og behandling av visceral smerte
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
GB0223040D0 (en) Therapeutic compounds
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
NO20053455L (no) Anvendelse av en kombinasjon inneholdende en ikke-nukleosid revers transkriptase inhibitor (NNRTI) med en inhibitor av cytokrom P450 sa som protease inhibitorer
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
DK1296972T3 (da) Arylmethylamin-derivater til anvendelse som tryptaseinhibitorer
WO2003092606A3 (en) Cholinesterase inhibitors to prevent injuries caused by chemicals
WO2004006912A3 (en) Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
HUP0203682A2 (hu) Eljárás foszfodiészteráz-4 inhibitor beadására
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
PT1206444E (pt) Compostos que inibem a actividade da triptase
NO20042758L (no) Fremgangsmate for behandling av en pasient som krever analgesi.
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
WO2006015283A3 (en) Treatment of benign prostatic hyperplasia
NO20073610L (no) Nye substituerte tiofenpyrimidinonderivater som inhibitorer for 17 β-hydroksysteroiddehydrogenase
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU